Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis

DSpace/Manakin Repository

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis

Show simple item record

dc.contributor.author Esserman, Laura J
dc.contributor.author Dowsett, Mitch
dc.contributor.author Slingerland, Joyce M
dc.contributor.author Ozanne, Elissa M.
dc.date.accessioned 2011-04-28T04:16:11Z
dc.date.issued 2005
dc.identifier.citation Esserman, Laura J., Elissa M. Ozanne, Mitch Dowsett, and Joyce M. Slingerland. 2005. Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis. Breast Cancer Research 7(6): R1153-R1158. en_US
dc.identifier.issn 1465-5411 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:4878920
dc.description.abstract Introduction: Breast Cancer Prevention Trial (BCPT) and Multiple Outcomes of Raloxifene (MORE) data have been interpreted to indicate that tamoxifen reduces the risk of ER+ but not ER- breast carcinogenesis. We explored whether these data also support an alternative hypothesis, that tamoxifen influences the natural history of both ER+ and ER- cancers, that it may be equally effective in abrogating or delaying ER- and ER+ carcinogenesis, and place selection pressure, in some cases, for the outgrowth of ER- cancers. Methods: BCPT and MORE data were used to investigate whether: first, tamoxifen could reduce equally the emergence of ER- and ER+ tumors; and second, tamoxifen could select a fraction of emerging ER+ cancers and promote their transformation to ER- cancers. Assuming that some proportion, Z, of ER+ tumors becomes ER- after tamoxifen exposure and that the risk reduction for both ER- and ER+ tumors is equal, we solved for both the transformation rate and the risk reduction rate. Results: If tamoxifen equally reduces the incidence of ER+ and ER- tumors by 60%, the BCPT results are achieved with a transformation of approximately Z = 20% of ER+ to ER- tumors. Validation with MORE data using an equal risk reduction of 60% associated with tamoxifen produces an almost identical transformation rate Z of 23%. Conclusion: Data support an alternative hypothesis that tamoxifen may promote ER- carcinogenesis from a precursor lesion that would otherwise have developed as ER+ without tamoxifen selection. en_US
dc.language.iso en_US en_US
dc.publisher BioMed Central en_US
dc.relation.isversionof doi:10.1186/bcr1342 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1410777/pdf/ en_US
dash.license LAA
dc.title Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Breast Cancer Research en_US
dash.depositing.author Ozanne, Elissa M.
dc.date.available 2011-04-28T04:16:11Z
dash.affiliation.other HMS^Radiology-Massachusetts General Hospital en_US

Files in this item

Files Size Format View
1410777.pdf 131.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters